Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 3, 2004, Pages 430-436

  Ehrenforth, S ^a   Nemes, L ^b   Mannhalter, C ^c   Rosendaal, F R ^d   Koder, S ^c   Zoghlami Rintelen, C ^c   Scharrer, I ^a   Pabinger, Ingrid ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b National Institute of Haematology and Immunology Budapest   (Hungary)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Factor V Leiden; Homozygous factor V:G1691A; Oral contraceptives; Prothrombin G20210A variation; Thrombophilia; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; CYTOSINE; GLYCINE; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; THREONINE; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENE MUTATION; GENETIC RISK; GENOTYPE; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; STANDARDIZATION; SYMPTOMATOLOGY; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; CHILD; CLINICAL TRIAL; ENVIRONMENT; EUROPE; GENETICS; HETEROZYGOTE DETECTION; HOMOZYGOTE; MIDDLE AGED; MULTICENTER STUDY; POINT MUTATION; RISK FACTOR; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; ENVIRONMENT; EUROPE; FACTOR V; FEMALE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; MIDDLE AGED; POINT MUTATION; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 6944234994     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00606.x     Document Type: Article

References (39)

1. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
2. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90 1004-8.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
6. den Heijer MD, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-5.
7. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtman LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolat reductase. Nat Genet 1995; 10: 111-3.
8. Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520-2.
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
10. Rees DC, Cox M, Cleg JB. World distribution of factor V Leiden. Lancet 1995; 348: 1133.
11. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305.
12. Tordai A, Rajczy K, Penzes M, Sarkadi B, Varadi A. Prevalence of factor V Leiden (Arg506Gln) in Hungary. Br J Haematol 1997; 99: 464-72.
13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504.
14. Ehrenforth S, Klinke S, von Depka Prondzinski M, Kreuz W, Ganser A, Schaffer I. APC-Resistenz und venöse Thrombophilie. Molekluargenetische Prävalenzstudie in der deutschen Bevö lkerung. Dtsch Med Wschr 1999; 124: 783-7.
15. Koelemann BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
16. Zöller B, Berntsdotter A, de Frutos PG, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
17. Ehrenforth S, von Depka Prondsinski M, Aygören-Pürsün E, Nowak-Göttl U, Scharrer I, Ganser A. Study of the prothrombin gene 20210 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999; 19: 276-80.
18. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gln mutation in the gene for factor V. N Engl J Med 1994; 331: 1559.
19. Hopmeier P, Krugluger W. Factor V Leiden and thrombophilia. N Engl J Med 1994; 332: 1381.
20. Samama M, Trossaert M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 86: 4700.
21. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487.
22. Emmerich J, Alhenc-Gelas M, Aillaud MF, Juhan-Vague I, Jude B, Garcin JM, Dreyfus M, de Moerloose P, Le Querrec A, Priollet P, Berruyer M, Vallantin X, Wolf M, Aiach M, Fiessinger JN. Clinical features in 36 patients homozygous for the Arg506 → Gln factor V mutation. Thromb Haemost 1997; 77: 620.
23. Vandenbroucke JP, Koster T, Briet E, Bertina PH, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453.
24. Pabinger I, Nemes L, Rintelen C, Koder S, Lechler E, Loreth RM, Kyrle PA, Scharrer I, Sas G, Lechner K, Mannhalter C, Ehrenforth S. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000; 1: 37-41.
25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic, disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346 1575-82.
26. Martinelli I, Cattaneo M, Taioli E, De Stefano V, Chiusolo P, Mannucci PM. Genetic risk factors for superficial vein thrombosis. Thromb Haemost 1999; 82: 1215-7.
27. Bergquist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. Br Med J 1985; 292 658-9.
28. Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996; 24: 745-9.
29. Bounameaux H, Reber-Wasem MA. Superficial vein thrombophlebitis and deep vein thrombosis. Arch Intern Med 1997; 157: 1822-4.
30. Makris M, Preston EE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Hemost 1997; 78: 1426-9.
31. Tosetto A, Rodeghiero F, Martinelli I, De Stefano V, Missiaglia E, Chiusolo P, Mannucci PM. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol 1998; 103: 871-6.
32. Zöller B, Svensson P, Dahlbäck B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998; 91: 2210-1.
33. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-6.
34. Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
35. Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep vein thrombosis. Thromb Haemost 1998; 79: 254-8.
36. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997; 97: 804-6.
37. Rintelen C, Mannhalter C, Lechner K, Eichinger S, Kyrle PA, Papagiannopoulos M, Schneider B, Pabinger I. No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene. Blood Coagul Fibrinolysis 1999; 10: 101-5.
38. Salomon O, Steinberg D, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism - prevalence and risk assessment. Arteriol Thromb Vasc Biol 1999; 19: 511-8.
39. Hille ET, Westendorp RG, Vandenbroucke HP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89: 1963-7.